search
Back to results

Maternal Stress on Human Milk and Infant Outcomes

Primary Purpose

Postpartum Depression, Preterm Labor

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Mindfulness-based intervention (with a focus on self-compassion; MBSC)
Sponsored by
University of Idaho
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Postpartum Depression focused on measuring Maternal stress, Mindfulness, Human milk bioactives, Infant metabolome, Maternal transcriptome, Infant transcriptome

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Mothers of preterm infants (<36 weeks gestation) at Oregon Health and Sciences University

Exclusion Criteria:

-

Sites / Locations

  • Kootenai HealthRecruiting
  • Oregon Health & Science UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control

Mindfulness-based intervention (with a focus on self-compassion; MBSC)

Arm Description

Control group will receive link to a free 8-week Mindfulness Based Stress Reduction intervention AFTER the 8-weel trial period.

8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.

Outcomes

Primary Outcome Measures

Maternal Stress - Biomarker Change
Salivary cortisol - Change from Baseline cortisol to 4 and 8 weeks
Maternal Stress - Psychometric Measure Change
Perceived Stress Scale (PSS) - Change from Baseline PSS to 4 and 8 weeks The Perceived Stress Scale (PSS) is validated and the most widely used instrument to measure perception of stress. The PSS includes 14 questions inquiring about feelings and thoughts during the past month expressed through frequency. The PSS will be used pre-intervention, post-intervention (8 weeks), and at the mid-point of the intervention (4 weeks). The scale for each question ranges from 0-4. The PSS measures how often the responder found life to be unpredictable, uncontrollable, and overloaded. Higher score indicates higher perceived stress. The total score ranges between 0-56.
Maternal Self-compassion - Biomarker Change
Salivary oxytocin - Change from Baseline oxytocin to 4 and 8 weeks
Maternal Self-compassion - Psychometric Measure Change
Self-Compassion Scale-Short Form (SCS-SF) - Change from Baseline SCS-SF to 4 and 8 weeks The Self-Compassion Scale-Short Form (SCS-SF)19 is a shortened and highly correlated (r ≥ 0.97) scale (12 items) from the original 26-item SCS. The SCS-SF measures six key components of self-compassion using a scale that ranges from 1-5: self-kindness, self-judgement, common humanity, isolation, mindfulness, and over-identification. Self-compassion is associated with psychological well-being and is therefore often measured alongside stress and anxiety. High score indicates higher self-compassion. The total score ranges between 0-60.

Secondary Outcome Measures

Human Milk Proteins & Peptides Change
Protein and peptide profiles will be measured using proteomic & peptidomic analyses to assess human milk protein and peptide changes from baseline to 4 and 8 weeks as a function of maternal changes in stress/self-compassion. These are measured outcomes.
Maternal Metabolomic & Transcriptomic Changes
Maternal metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to changes in stress/self-compassion. These are measured outcomes.
Infant Metabolomic & Transcriptomic Changes
Infant metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to maternal changes in stress/self-compassion, and human milk protein/peptide profile changes. These are measured outcomes.

Full Information

First Posted
November 17, 2020
Last Updated
September 1, 2023
Sponsor
University of Idaho
Collaborators
Oregon Health and Science University, Oregon State University, National Institute of General Medical Sciences (NIGMS), Kootenai Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04821544
Brief Title
Maternal Stress on Human Milk and Infant Outcomes
Official Title
Effects of Maternal Stress on Human Milk Composition and Subsequent Infant Outcomes
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2021 (Actual)
Primary Completion Date
June 30, 2025 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Idaho
Collaborators
Oregon Health and Science University, Oregon State University, National Institute of General Medical Sciences (NIGMS), Kootenai Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The overarching purpose of this study is to determine if a modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) will reduce stress and increase self-compassion in mothers of preterm infants and beneficially modify the human milk produced, and subsequently improve infant health.
Detailed Description
During every two-week period, newly admitted preterm infants (<36 weeks gestational age) will be recruited at performance site OHSU NICU and block-randomized to either control (standard of care) or intervention (modified 8-week mindfulness-based intervention (with a focus on self-compassion; MBSC) group. The purpose of the nested cohorts is to minimize the postpartum time difference among cohort mothers. Each nested MBSC cohort will undergo the 8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator. Maternal data: The Perceived Stress Scale (PSS) and Self-Compassion Scale-Short Form (SCS-SF) will be given to mothers from both groups pre- and post-intervention, and during the 4th week. Saliva, urine, stool, and human milk samples will be collected at the same time points as above. Additional maternal data include: age, race, height, weight (pre-pregnancy and last weight before delivery), parity, delivery mode, chorioamnionitis, preeclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome, antenatal antibiotics, anti-depressants or other mood-altering/neurochemical medications (current and during pregnancy), diagnosis of depression or other mental illness within the previous 5 years, history of postpartum depression and postpartum psychosis, diabetes, hypertension, heart disease, and any inflammatory or autoimmune diseases. Infant data: Gestational age, birth weight, ventilation requirement, surgical interventions, patent ductus arteriosus, growth, nutrition prescriptions, saliva, urine and stool samples. Data collection: All data (not including biosamples) will be collected using REDCap hosted within the UI system. Sample measurements: Maternal salivary cortisol (marker of stress) and oxytocin (marker of anxiety and "social-closeness") concentrations will be measured using ELISA. Human milk proteins will be identified using mass spectrometry-based proteomics. Following proteomic analyses, targeted proteins will be quantified using ELISA and Western Blot. Both maternal and infant saliva, urine and stool samples will be used for metabolomic and transcriptomic sequencing to identify metabolic and molecular changes, respectively, in both mothers and infants. Infant systemic oxidative stress will be measured through urine F2-isoprostanes concentrations (ELISA), and infant intestinal inflammation will be determined with stool calprotectin concentrations (ELISA).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postpartum Depression, Preterm Labor
Keywords
Maternal stress, Mindfulness, Human milk bioactives, Infant metabolome, Maternal transcriptome, Infant transcriptome

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
Control group will receive link to a free 8-week Mindfulness Based Stress Reduction intervention AFTER the 8-weel trial period.
Arm Title
Mindfulness-based intervention (with a focus on self-compassion; MBSC)
Arm Type
Experimental
Arm Description
8-week MBSC intervention with a focus on increasing self-compassion. The MBSC program includes previously developed daily mindfulness practices, guided meditations, routine mindfulness prompts, and four video conference group sessions with a certified mindfulness facilitator.
Intervention Type
Behavioral
Intervention Name(s)
Mindfulness-based intervention (with a focus on self-compassion; MBSC)
Intervention Description
8-week MBSC intervention with a focus on increasing self-compassion
Primary Outcome Measure Information:
Title
Maternal Stress - Biomarker Change
Description
Salivary cortisol - Change from Baseline cortisol to 4 and 8 weeks
Time Frame
Baseline to 4 and 8 weeks
Title
Maternal Stress - Psychometric Measure Change
Description
Perceived Stress Scale (PSS) - Change from Baseline PSS to 4 and 8 weeks The Perceived Stress Scale (PSS) is validated and the most widely used instrument to measure perception of stress. The PSS includes 14 questions inquiring about feelings and thoughts during the past month expressed through frequency. The PSS will be used pre-intervention, post-intervention (8 weeks), and at the mid-point of the intervention (4 weeks). The scale for each question ranges from 0-4. The PSS measures how often the responder found life to be unpredictable, uncontrollable, and overloaded. Higher score indicates higher perceived stress. The total score ranges between 0-56.
Time Frame
Baseline to 4 and 8 weeks
Title
Maternal Self-compassion - Biomarker Change
Description
Salivary oxytocin - Change from Baseline oxytocin to 4 and 8 weeks
Time Frame
Baseline to 4 and 8 weeks
Title
Maternal Self-compassion - Psychometric Measure Change
Description
Self-Compassion Scale-Short Form (SCS-SF) - Change from Baseline SCS-SF to 4 and 8 weeks The Self-Compassion Scale-Short Form (SCS-SF)19 is a shortened and highly correlated (r ≥ 0.97) scale (12 items) from the original 26-item SCS. The SCS-SF measures six key components of self-compassion using a scale that ranges from 1-5: self-kindness, self-judgement, common humanity, isolation, mindfulness, and over-identification. Self-compassion is associated with psychological well-being and is therefore often measured alongside stress and anxiety. High score indicates higher self-compassion. The total score ranges between 0-60.
Time Frame
Baseline to 4 and 8 weeks
Secondary Outcome Measure Information:
Title
Human Milk Proteins & Peptides Change
Description
Protein and peptide profiles will be measured using proteomic & peptidomic analyses to assess human milk protein and peptide changes from baseline to 4 and 8 weeks as a function of maternal changes in stress/self-compassion. These are measured outcomes.
Time Frame
Baseline to 4 and 8 weeks
Title
Maternal Metabolomic & Transcriptomic Changes
Description
Maternal metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to changes in stress/self-compassion. These are measured outcomes.
Time Frame
Baseline to 4 and 8 weeks
Title
Infant Metabolomic & Transcriptomic Changes
Description
Infant metabolomic pathways & gene activation changes from baseline to 4 and 8 weeks in response to maternal changes in stress/self-compassion, and human milk protein/peptide profile changes. These are measured outcomes.
Time Frame
Baseline to 4 and 8 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Mothers of preterm infants (<36 weeks gestation) at Oregon Health and Sciences University Exclusion Criteria: -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yimin Chen, PhD
Phone
2088857264
Email
yiminc@uidaho.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yimin Chen, PhD
Organizational Affiliation
University of Idaho
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kootenai Health
City
Coeur d'Alene
State/Province
Idaho
ZIP/Postal Code
83814
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brook Lang, MD
Facility Name
Oregon Health & Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brian Scottoline, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
IPD will be available upon request.

Learn more about this trial

Maternal Stress on Human Milk and Infant Outcomes

We'll reach out to this number within 24 hrs